GenSight Biologics Reports 2026 Interim Financial Results

GenSight Biologics has reported interim financial results for the first half of 2026 with notable business updates. The company collected €6.5 million from early access programs but faced a reported IFRS revenue of €(1.2) million. Operating cash use reduced by 37% to €1.6 million. The technology transfer to Catalent was completed, enabling the production of a new GMP batch.

Clinical updates include the progress of the REVISE dose-ranging study, expected to conclude by December 2026. Preparations for the RECOVER Phase III trial continue, with activities pending based on securing financing by March 2027. GenSight intends to ensure seamless supply and mitigate any potential interruptions.

The statutory auditors highlighted a material uncertainty related to the company's going concern, primarily due to the need for structural financing. Though early access revenues and research tax credits provide some financial cushion, a €41 million total cash requirement until September 2027 implies significant funding challenges.